- Home
- EQ vs ITRM Comparison
EQ vs ITRM Comparison
Compare EQ & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- ITRM
- Stock Information
- Founded
- EQ 2017
- ITRM 2015
- Country
- EQ United States
- ITRM Ireland
- Employees
- EQ N/A
- ITRM N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- EQ Health Care
- ITRM Health Care
- Exchange
- EQ Nasdaq
- ITRM Nasdaq
- Market Cap
- EQ 24.8M
- ITRM 24.7M
- IPO Year
- EQ 2018
- ITRM 2018
- Fundamental
- Price
- EQ $0.74
- ITRM $1.79
- Analyst Decision
- EQ Buy
- ITRM Strong Buy
- Analyst Count
- EQ 2
- ITRM 1
- Target Price
- EQ $5.00
- ITRM $5.00
- AVG Volume (30 Days)
- EQ 304.3K
- ITRM 7.2M
- Earning Date
- EQ 11-13-2024
- ITRM 11-14-2024
- Dividend Yield
- EQ N/A
- ITRM N/A
- EPS Growth
- EQ N/A
- ITRM N/A
- EPS
- EQ N/A
- ITRM N/A
- Revenue
- EQ $45,914,000.00
- ITRM N/A
- Revenue This Year
- EQ N/A
- ITRM N/A
- Revenue Next Year
- EQ N/A
- ITRM N/A
- P/E Ratio
- EQ N/A
- ITRM N/A
- Revenue Growth
- EQ 7.70
- ITRM N/A
- 52 Week Low
- EQ $0.48
- ITRM $0.81
- 52 Week High
- EQ $3.25
- ITRM $2.50
- Technical
- Relative Strength Index (RSI)
- EQ 40.86
- ITRM 68.50
- Support Level
- EQ $0.66
- ITRM $1.25
- Resistance Level
- EQ $0.77
- ITRM $1.83
- Average True Range (ATR)
- EQ 0.08
- ITRM 0.14
- MACD
- EQ -0.01
- ITRM 0.04
- Stochastic Oscillator
- EQ 26.09
- ITRM 93.55
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.